UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annals of oncology, ISSN 0923-7534, 05/2011, Volume 22, Issue 5, pp. 1221 - 1227
chemotherapy-induced necrosis | Ewing sarcoma | high-dose chemotherapy | Chemotherapy-induced necrosis | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Myeloablative Agonists - therapeutic use | Bone Neoplasms - mortality | Doxorubicin - therapeutic use | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Child, Preschool | Male | Sarcoma, Ewing - mortality | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Dactinomycin - therapeutic use | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Kaplan-Meier Estimate | Etoposide - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Peripheral Blood Stem Cell Transplantation | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3497 - 3505
Life Sciences & Biomedicine | Oncology | Science & Technology | Myeloablative Agonists - therapeutic use | Graft vs Host Disease - epidemiology | Busulfan - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Cyclophosphamide - therapeutic use | Incidence | Bayes Theorem | Adult | Female | Graft vs Host Disease - prevention & control | Aged | Transplantation Conditioning - methods | Index Medicus | ORIGINAL REPORTS | Bone1
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 10/2016, Volume 51, Issue 10, pp. 1369 - 1375
Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Humans | Middle Aged | Ovary - physiology | Myeloablative Agonists | Young Adult | Pilot Projects | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Leuprolide - therapeutic use | Follicle Stimulating Hormone - blood | Adult | Female | Ovary - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Child | Gonadotropin-Releasing Hormone - agonists | Ovarian Function Tests | Chemotherapy | Usage | Follicle-stimulating hormone | Cancer cells | Research | Hematopoietic stem cells | Cancer | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2970 - 2976
total-lung irradiation | lung metastases | Ewing's sarcoma | high-dose chemotherapy | Lung metastases | Total-lung irradiation | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pneumology | Myeloablative Agonists - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Bone Neoplasms - secondary | Child, Preschool | Lung Neoplasms - radiotherapy | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Young Adult | Lung Neoplasms - secondary | Neoplasm Metastasis - drug therapy | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Neoplasm Metastasis - radiotherapy | Etoposide - therapeutic use | Combined Modality Therapy | Lung Neoplasms - therapy | Sarcoma, Ewing - drug therapy | Sarcoma, Ewing - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Sarcoma, Ewing - radiotherapy | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | total-lung | Klinisk medicin | Cancer and Oncology | irradiation | Cancer och onkologi
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2017, Volume 23, Issue 9, pp. 1417 - 1421
Hematology, Oncology and Palliative Medicine | HCT activity | Trends | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Hematologic Neoplasms - mortality | Humans | Transplantation, Autologous | Hematologic Neoplasms - pathology | Methotrexate - therapeutic use | Transplantation, Homologous | Hematopoietic Stem Cells - immunology | Graft vs Host Disease - mortality | Antilymphocyte Serum - therapeutic use | Adult | Transplantation Conditioning - methods | Child | Hematopoietic Stem Cell Transplantation - trends | Histocompatibility Testing | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Tissue Donors - classification | Calcineurin Inhibitors - therapeutic use | Hematopoietic Stem Cells - cytology | Survival Analysis | Graft vs Host Disease - prevention & control | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Alemtuzumab - therapeutic use | Tissue Donors - supply & distribution | Bone marrow | Analysis | Hematopoietic stem cells | Medical colleges | Medical research | Medicine, Experimental | Index Medicus | trends
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 02/2019, Volume 54, Issue 2, pp. 204 - 211
Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Myeloablative Agonists - therapeutic use | Primary Myelofibrosis - mortality | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Transplantation Conditioning - mortality | Transplantation, Homologous | Carmustine - therapeutic use | Antineoplastic Agents - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Busulfan - therapeutic use | Primary Myelofibrosis - complications | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Transplantation Conditioning - standards | Survival Analysis | Aged | Primary Myelofibrosis - therapy | Chimerism | Hematopoietic Stem Cell Transplantation - methods | Care and treatment | Myelofibrosis | Patient outcomes | Stem cells | Development and progression | Methods | Stem cell transplantation | CD3 antigen | Patients | Hematopoietic stem cells | Hemopoiesis | Urea | Fludarabine | Melphalan | Busulfan | Conditioning | Index Medicus
Journal Article
American journal of hematology, ISSN 0361-8609, 10/2018, Volume 93, Issue 10, pp. 1211 - 1219
Life Sciences & Biomedicine | Hematology | Science & Technology | Myeloablative Agonists - therapeutic use | Thiotepa - therapeutic use | Confidence Intervals | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Humans | Middle Aged | Drug Evaluation | Male | Living Donors | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Allografts | Bone Marrow Transplantation | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Transplantation Conditioning - adverse effects | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Busulfan - adverse effects | Busulfan - therapeutic use | Vidarabine - adverse effects | Proportional Hazards Models | Combined Modality Therapy | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Thiotepa - adverse effects | Cyclophosphamide | Transplantation | Comparative analysis | Thiotepa | Stem cells | Fludarabine | Cord blood | Donors | Transplants & implants | Myeloid leukemia | Leukemia | Remission | Busulfan | Acute myeloid leukemia | Index Medicus
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 4, pp. 723 - 730
Hematology, Oncology and Palliative Medicine | Cidofovir | BK virus | Hemorrhagic cystitis | Hematopoietic stem cell transplantation | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Polyomavirus Infections - immunology | Cytosine - analogs & derivatives | Polyomavirus Infections - etiology | BK Virus - drug effects | Hematologic Neoplasms - mortality | Humans | Middle Aged | Hemorrhage - mortality | Cystitis - immunology | Male | Hematologic Neoplasms - pathology | Transplantation, Homologous | Hemorrhage - etiology | Hematopoietic Stem Cell Transplantation - adverse effects | Tumor Virus Infections - immunology | Tumor Virus Infections - therapy | Adult | Female | Cytosine - therapeutic use | Retrospective Studies | Cystitis - etiology | Glomerular Filtration Rate | Drug Administration Schedule | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Hemorrhage - therapy | Hemorrhage - immunology | Cystitis - therapy | Graft Survival | Tumor Virus Infections - mortality | Cystitis - mortality | Polyomavirus Infections - mortality | Polyomavirus Infections - therapy | Survival Analysis | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Tumor Virus Infections - etiology | Viral Load - drug effects | BK Virus - physiology | Care and treatment | Cystitis | Hematopoietic stem cells | Stem cells | Medical research | Leptin | Medicine, Experimental | Epstein-Barr virus | Index Medicus | Life Sciences | Cancer
Journal Article
Blood, ISSN 0006-4971, 10/2011, Volume 118, Issue 16, pp. 4346 - 4352
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Myeloablative Agonists - therapeutic use | Amyloidosis - therapy | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Transplantation, Autologous | Treatment Outcome | Amyloidosis - drug therapy | Hematologic Tests | Antineoplastic Agents, Alkylating - administration & dosage | Melphalan - therapeutic use | Immunoglobulin Light Chains - metabolism | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Melphalan - administration & dosage | Aged, 80 and over | Myeloablative Agonists - administration & dosage | Adult | Female | Aged | Amyloidosis - metabolism | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | Clinical Trials and Observations | Transplantation
Journal Article
British journal of haematology, ISSN 0007-1048, 10/2011, Volume 155, Issue 2, pp. 218 - 234
paediatrics | graft‐versus‐host disease | immune | cord blood transplantation | immunology | Graft-versus-host disease | Immunology | Immune | Paediatrics | Cord blood transplantation | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Myeloablative Agonists - therapeutic use | Recombinant Proteins - therapeutic use | Whole-Body Irradiation | Antibodies, Neoplasm - therapeutic use | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Neoplasms - surgery | Humans | Child, Preschool | Male | Antibiotic Prophylaxis | Melphalan - therapeutic use | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Busulfan - administration & dosage | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Antibodies, Monoclonal, Humanized - administration & dosage | Female | Leukocyte Count | Retrospective Studies | Transplantation Conditioning - methods | Child | Graft vs Host Disease - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Busulfan - therapeutic use | T-Lymphocytes | Neutrophils | Graft Survival | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Cord Blood Stem Cell Transplantation - methods | Melphalan - administration & dosage | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Antilymphocyte Serum | Genetic Diseases, Inborn - surgery | Vidarabine - administration & dosage | Pediatrics | Immunoglobulins | Immunotherapy | Stem cells | Transplantation | Comparative analysis | Health aspects | Index Medicus
Journal Article